Document:

rkda-ex101_6.htm

Exhibit 10.1

 

 

PROMISSORY NOTE

 

This Promissory Note (this "Note") is made on 4/16/2020 by Arcadia Biosciences, Inc. (together with its successors and assigns, "Borrower") in favor of MidFirst Bank (together with its successors and assigns, "Lender").

 

PROMISE TO PAY. Borrower promises to pay to Lender, or order, in lawful money of the United States of America, the principal amount of $1,107,700, together with interest on the unpaid principal balance from 4/16/2020, calculated as described in the "INTEREST CALCULATION METHOD" paragraph below using an interest rate of one percent (1.000%), until paid in full. The interest rate may change under the terms and conditions of the "INTEREST AFTER DEFAULT" section.

 

PAYMENT. No payment of principal or interest will be due until the first Business Day of the seventh month after 4/16/2020 (the "First Payment Date"). On the First Payment Date, and on each first Business Day from the First Payment Date until the first Business Day of the 24th month after 4/16/2020, Borrower shall pay principal plus interest accrued under this Note in 18monthly installments based on an 18 month amortization schedule determined by Lender on the principal balance of this Note owing on the First Payment Date with interest accruing as set forth in this Note. In addition to any of the foregoing amounts, on the first Business Day of the 24th month following 4/16/2020, Borrower shall pay all then accrued and unpaid Indebtedness.

 

Unless otherwise required by applicable law, payments will be applied as Lender directs in its sole discretion. All payments must be made in U.S. dollars and must be received by Lender at: Payment Processing Department, PO Box 76149, Oklahoma City, OK 73147-2149. All payments must be received by Lender consistent with any written payment instructions provided by Lender. 

 

INTEREST CALCULATION METHOD. Interest on the Indebtedness is computed on a 30/360 basis; that is, by applying the ratio of the interest rate over a year of 360 days, multiplied by the outstanding principal balance, multiplied by the actual number of days the principal balance is outstanding. All interest payable on the Indebtedness is computed using this method.

 

PRINCIPAL FORGIVENESS. Some, or all, of the principal of the Indebtedness may be forgiven as permitted under Section 1106 (as such section is hereafter amended and interpreted by the Small Business Administration) of the Coronavirus Aid, Relief, and Economic Security Act (or the CARES Act) of 2020 (“Debt Forgiveness”). Borrower, not Lender, is responsible for ensuring that Borrower is eligible for Debt Forgiveness. Borrower shall, within 12 weeks after 4/16/2020, request Debt Forgiveness, to the extent Borrower is eligible for Debt Forgiveness and provides Lender with all documentation Lender requires to support Borrower’s request for Debt Forgiveness. Lender will, within 60 days after Lender receives Borrower’s Debt Forgiveness request and all required documentation for Debt Forgiveness (the “Debt Forgiveness Determination”), confirm whether Borrower qualifies for Debt Forgiveness, but Lender will not be liable to Borrower for Lender’s determination. Borrower waives any claim against Lender related to Debt Forgiveness.

 

PREPAYMENT. Borrower may pay without penalty all or a portion of the amount owed earlier than it is due. Early payments will not, unless agreed to by Lender in writing, relieve Borrower of Borrower's obligation to continue to make payments under the payment schedule. Rather, early payments will reduce the principal balance due and may result in Borrower's making fewer payments. Borrower agrees not to send Lender payments marked "paid in full", "without recourse", or similar language. If Borrower sends such a payment, Lender may accept it without losing any of Lender's rights under this Note or the other Loan Documents, and Borrower will remain obligated to pay any further amount owed to Lender. All written communications concerning disputed amounts, including any check or other payment instrument that indicates that the payment constitutes "payment in full" of the amount owed or that is tendered with other conditions or limitations or as full satisfaction of a disputed amount must be mailed or delivered to: MidFirst Bank, P.O. Box 76149 Oklahoma City, OK 73147-2149. 

 

LATE CHARGE AND DISHONORED ITEM FEE. If a payment is 10 days or more late, then Borrower will be charged 5.00% of the unpaid portion of the regularly scheduled payment. Borrower shall pay a fee to Lender of $25.00 if Borrower makes a payment on the Indebtedness and the check or other payment order including any preauthorized charge with which Borrower pays is later dishonored.

 

INTEREST AFTER DEFAULT. Upon default, including failure to pay upon final maturity, the interest rate on the Indebtedness shall automatically increase by 6.00 percentage points. However, in no event will the interest rate exceed the maximum interest rate limitations under applicable law. 

 

BORROWER'S REPRESENTATIONS AND WARRANTIES. Borrower represents and promises to Lender that: 

 

Loan Purpose. The primary purpose of the Loan is business, and not personal, family or household, or personal investment.

 

Existence and Good Standing. If Borrower is other than a natural person, Borrower is duly formed, in existence and good standing in its jurisdiction of formation, and is registered and in good standing in all other jurisdictions in which it is required to register. 

 

Authority. If Borrower is other than a natural person, Borrower is duly authorized to enter into this Note and the Loan Documents. Borrower has duly executed and delivered to Lender this Note and the Loan Documents. If Borrower is other than a natural person, then the natural person, or persons, signing this Note and the Loan Documents is, and was, and he or she also represents and promises to Lender, that he or she is and was, duly authorized to execute and deliver this Note and the Loan Documents to Lender. 

 

Exhibit 10.1

 

 

No Conflict or Breach. Borrower’s execution and delivery of this Note and the Loan Documents does not breach or conflict with any (a) if Borrower is other than a natural person, of Borrower’s governing documents, or (b) contract, agreement or other arrangement or obligation of Borrower. 

 

Capacity. No natural person executing this Note and the Loan Documents, on behalf of himself, herself or any entity, lacks capacity to contract by age, mind or other form of diminished capacity. 

 

SBA Payment Protection Program. Borrower knows and understands all terms of Coronavirus Aid, Relief, and Economic Security Act (or the CARES Act) of 2020, and all SBA rules and guidance regarding the Payment Protection Program, and has not relied, and will not rely, on Lender or any of Lender’s shareholders, directors, officers, agents, employees, or representatives in determining whether Borrower is eligible for said Program or Debt Forgiveness. Borrower acknowledges that the SBA has limited funds for said Program, and funds will be disbursed on a first come, first serve basis by the SBA. Therefore, Borrower holds Lender harmless from all claims related to Borrower’s loan not being funded because the funding of said Program has been exhausted or expired.

 

DEFAULT. Each of the following constitutes an Event of Default under this Note:

 

Payment Default. Borrower fails to make any payment when due under the Indebtedness. 

 

Other Defaults. Borrower fails to comply with or to perform any other term, obligation, covenant or condition contained in this Note or in any of the other Loan Documents or to comply with or to perform any term, obligation, covenant or condition contained in any other agreement between Lender and Borrower. 

 

Default in Favor of Third Parties. Borrower defaults under any agreement with any person that may materially affect any of Borrower's property or ability to perform his, her or its obligations under this Note or any of the Loan Documents. 

 

False Statements. Any warranty, representation or statement made or furnished to Lender by Borrower or on Borrower's behalf under this Note or the Loan Documents is false or misleading in any material respect, either now or at the time made or furnished or becomes false or misleading at any time thereafter. 

 

Insolvency; Existence. (1) Borrower dissolves (regardless of whether election to continue is made; (2) any member or partner of Borrower withdraws from its ownership in Borrower; (3) any interest-holder or shareholder of Borrower owning, controlling or holding more than 25% of the shares (directly or indirectly) or interests of Borrower sells his or her interest or shares in Borrower; (4) Borrower’s existence is otherwise terminated; (5) Borrower (if a natural person) or any member, partner or interest holder of Borrower dies; (6) Borrower is or becomes insolvent; (7) a receiver is appointed for any part of Borrower's property or business; (8) Borrower makes any assignment for the benefit of creditors; or (9) any proceeding under any bankruptcy or insolvency laws is commenced by or against Borrower. 

 

Adverse Change. A material adverse change occurs in Borrower's financial condition, or Lender believes the prospect of payment or performance of the Indebtedness is impaired.

 

RIGHTS AND REMEDIES ON DEFAULT. If an Event of Default occurs under this Note, at any time thereafter, Lender may exercise any one or more of the following rights and remedies:

 

Accelerate Indebtedness. Lender may declare the entire Indebtedness, including any prepayment penalty which Borrower would be required to pay, immediately due and payable, without notice of any kind to Borrower.

 

Election of Remedies. All of Lender's rights and remedies, whether evidenced by the Loan Documents or any other writing, at law or in equity, are cumulative and may be exercised singularly or concurrently. Lender’s election to pursue any remedy does not prevent Lender from pursuing any other remedy.

 

MISCELLANEOUS PROVISIONS. The following miscellaneous provisions are a part of this Note:

 

Amendments. The Loan Documents constitute the entire understanding and agreement of the parties as to the 

matters set forth in the Loan Documents. All prior and contemporaneous representations and discussions concerning such matters either are included in the Loan Documents or do not constitute an aspect of the agreement of the parties. Except as may be specifically set forth in this Note, no conditions precedent or subsequent, of any kind whatsoever, exist with respect to Borrower's obligations under the Loan Documents. No alteration of or amendment to the Loan Documents will be effective unless given in writing and signed by the party or parties sought to be charged or bound by the alteration or amendment.

 

Attorneys' Fees; Expenses. Borrower agrees to pay upon demand all of Lender's costs and expenses, including Lender's attorneys' fees and Lender's legal expenses, incurred in connection with the enforcement of the Loan Documents. Lender may hire or pay someone to help enforce the Loan Documents, and Borrower shall pay the costs and expenses of such enforcement. Costs and expenses include Lender's attorneys' fees and legal expenses whether or not there is a lawsuit, including attorneys' fees and legal expenses for bankruptcy proceedings (including efforts to modify or vacate any automatic stay or injunction), appeals, and any anticipated post-judgment collection services. All such costs and expenses shall become a part of the Indebtedness and bear interest as set forth above from the date incurred or paid by Lender to the date of repayment by Borrower. All such costs and expenses will be payable on demand.

 

Exhibit 10.1

 

 

Caption Headings. Caption headings in this Note are for convenience purposes only and are not to be used to interpret or define the provisions of this Note.

 

Re-execution or Replacement. The SBA has not yet mandated any form of, or specific requirements for a, promissory note for the Paycheck Protection Program. If Lender determines that the SBA has issued a form promissory note or specific requirements that this Note does not contain, then within 10 days after Lender’s written request, Borrower will execute a new form of promissory note provided that none of the loan amount, interest rate or repayment terms of the new promissory note is different from this Note.

 

Governing Law. The Loan Documents will be governed by federal law applicable to Lender and, to the extent not preempted by federal law, the laws of the State of Oklahoma without regard to its conflicts of law provisions. This Note has been accepted by Lender in the State of Oklahoma.

 

Notwithstanding the foregoing, if SBA becomes the holder of this Note, then this Note and the Loan Documents will be interpreted and enforced under federal law, including SBA regulations. Lender or SBA may use state or local procedures for filing papers, recording documents, giving notice, foreclosing liens, and other purposes. By using such procedures, SBA does not waive any federal immunity from state or local control, penalty, tax, or liability. As to this Note and the Loan Documents, Borrower may not claim or assert against SBA any local or state law to deny any obligation, defeat any claim of SBA, or preempt federal law.

 

No Waiver by Lender. Lender shall not be deemed to have waived any rights under the Loan Documents unless such waiver is given in writing and signed by Lender. No delay or omission on the part of Lender in exercising any right shall operate as a waiver of such right or any other right. A waiver by Lender of a provision of the Loan Documents does not prejudice or constitute a waiver of Lender's right otherwise to demand strict compliance with that provision or any other provision of the Loan Documents. No prior waiver by Lender, nor any course of dealing between Lender and Borrower, will constitute a waiver of any of Lender's rights or of any of Borrower's obligations as to any future transactions. Whenever the consent of Lender is required under the Loan Documents, the granting of such consent by Lender in any instance shall not constitute continuing consent to subsequent instances where such consent is required and in all cases such consent may be granted or withheld in the sole discretion of Lender.

 

Notices. Any notice required to be given under the Loan Documents must be given in writing, and will be effective when actually delivered, when deposited with a nationally recognized overnight courier, or, if mailed, when deposited in the United States mail, as first class, certified or registered mail postage prepaid, directed to, unless otherwise indicated in this Note or the Other Loan Documents, Lender at: Business Express, 11001 N Rockwell Ave, Oklahoma City, OK 73162, and to Borrower at the address set forth below Borrower’s signature on this Note. Any party may change its address for notices under the Loan Documents by giving formal written notice to the other parties, specifying that the purpose of the notice is to change the party's address.

 

Severability. If a court of competent jurisdiction finds any provision of the Loan Documents to be illegal, invalid, or unenforceable as to any circumstance, that finding will not make the offending provision illegal, invalid, or unenforceable as to any other circumstance. If feasible, the offending provision will be considered modified so that it becomes legal, valid and enforceable. If the offending provision cannot be so modified, it will be considered deleted from the Loan Documents. Unless otherwise required by law, the illegality, invalidity, or unenforceability of any provision of the Loan Documents will not affect the legality, validity or enforceability of any other provision of the Loan Documents.

 

Successors and Assigns. Borrower may not (without Lender’s prior written consent) assign to any party other 

than Lender any of its rights or obligations under the Loan Documents. Subject to the foregoing, the Loan

Documents are binding upon and inure to the benefit of the parties, their successors and assigns.

 

Survival of Representations and Warranties. All representations, warranties, and agreements made by

Borrower in the Loan Documents survive the execution and delivery of the Loan Documents, are continuing in

nature, and will remain in full force and effect until such time as the Indebtedness is paid in full.

 

Time is of the Essence. Time is of the essence in the performance of this Note.

 

Online Banking Access. Borrower requests that Lender add the loan made pursuant to this Note (the "Loan

Account") to Borrower's online banking profile, if any, in (a) iManage Business Banking ("iMBB") or (b) iManage

Business Express ("iMBX"; each of iMBB and iMBX is a "System"). If Borrower is not an administrator of

Borrower's iMBB profile, then Lender will grant Loan Account access only to Borrower's iMBB profile administrator.

The administrator may grant Borrower and other users access to the Loan Account on IMBB. The Loan Account

will be linked to Borrower's other accounts in the System and may have transfer capability. Borrower understands

that all users of the System who have access to the Loan Account may request loan advances through the System.

Borrower represents and warrants that Borrower has authority to link the Loan Account with other accounts in

Borrower's System profile. Lender may remove the Loan Account from Borrower's System profile at any time and

for any reason.

 

Indemnification of Lender. Borrower shall indemnify, defend (with Lender's selected counsel) and hold Lender

harmless from all claims, suits, obligations, damages, losses, costs and expenses (including, without limitation,

Lender's attorneys' fees), demands, liabilities, penalties, fines and forfeitures of any nature whatsoever that may

be asserted against Lender (or its officers, directors, employees and agents) or that Lender (or its officers,

directors, employees and agents) may incur arising out of, relating to, or in any way occasioned by (1) this Note,

 

Exhibit 10.1

 

the System or any matter related to Debt Forgiveness, or (2) the exercise of Lender's rights and remedies under

this Note (including, without limitation, exercising any rights collaterally assigned to Lender under this Note or any

other Loan Documents).

 

Waive Jury. Borrower waives the right to a jury trial in any action, proceeding, or counterclaim brought

by any party under the Loan Documents.

 

 

DEFINITIONS. The following capitalized words and terms shall have the following meanings when used in this Note.

Unless specifically stated to the contrary, all references to dollar amounts shall mean amounts in lawful money of the

United States of America. Words and terms used in the singular shall include the plural, and the plural shall include

the singular, as the context may require. Words and terms not otherwise defined in this Note shall have the meanings

attributed to such terms in the Uniform Commercial Code:

 

Application. The words "Application" mean the Paycheck Protection Program Borrower Application Form (SBA

Form 2483) that Borrower completed and submitted to Lender when applying for the Loan.

 

Business Day. The words "Business Day" mean each day of the week which is not a Saturday, Sunday or a

holiday recognized and observed by the Board of Governors of the Federal Reserve System.

 

Indebtedness. The word "Indebtedness" means the indebtedness evidenced by this Note and the other Loan

Documents, including all principal and interest together with all other indebtedness and costs and expenses for

which Borrower is responsible under the Loan Documents.

 

Lender. The word "Lender" means MidFirst Bank, its successors and assigns, and the SBA. 

 

Loan. The word "Loan" means the loan Lender extends to Borrower in the principal amount of $1,107,700 pursuant to this Note.

 

Loan Documents. The words "Loan Documents" mean this Note, the Application, and all other instruments evidencing, guarantying, securing, governing or relating to the Loan, and all amendments, modifications, renewals, substitutions and replacements of any of the foregoing Loan Documents. 

SBA. The word "SBA" means the Small Business Administration, an Agency of the United States of America.

 

BORROWER HAS READ AND UNDERSTOOD ALL PROVISIONS OF THIS NOTE, AND AGREES TO THIS NOTE’S TERMS. BORROWER HAS HAD THE OPPORTUNITY TO HAVE THIS NOTE REVIEWED BY LEGAL COUNSEL OF BORROWER’S CHOSING. THIS NOTE IS DATED 4/16/2020.

 

BY SIGNING THIS NOTE EACH PARTY REPRESENTS AND AGREES THAT: (A) THIS NOTE AND THE OTHER LOAN DOCUMENTS REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES, (B) THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES, AND (C) THIS WRITTEN AGREEMENT AND THE OTHER LOAN DOCUMENTS MAY NOT BE CONTRADICTED BY EVIDENCE OF ANY PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OR UNDERSTANDINGS OF THE PARTIES.

 

BORROWER:

Arcadia Biosciences, Inc.

 

By:

 

Pam Haley, CFO

 

Address:  Arcadia Biosciences, Inc.

202 Cousteau Place Suite 105

Davis, CA 95618

 

Exhibit 10.1Exhibit 4.2

 

 

 

COMPENSATION
POLICY FOR EXECUTIVES AND DIRECTORS

 

 

 

 

 

     

     

    

 

 

Executives
and Directors 

 

Compensation
Policy of Medigus Ltd. 

 

(the
“Company”) 

 

 

 

		1.	Objectives
                                         of the Company’s Compensation Policy

 

The
purpose of the Company’s compensation policy is to establish sustainable guidelines for the Company’s applicable organs
in determining the Company’s compensation to its Office Holders (as such term is defined below) in light of the following
objectives of such compensation:

 

	A.	To
                                         establish a correlation between the interests of the Company’s Office Holders and
                                         those of the Company and its shareholders.

 

	B.	To
                                         recruit and maintain qualified Office Holders, who may contribute to the Company’s
                                         financial and commercial success, given the unique challenges it faces and its business
                                         environment.

 

	C.	To
                                         provide incentives for the Company’s Office Holders, in order to ensure high-level
                                         operations without encouraging the taking of unreasonable risks.

 

	D.	To
                                         establish an appropriate balance between fixed compensation, compensation which incentivizes
                                         short-term results and compensation which reflects the Company’s long-term operation.

 

		2.	Compensation
                                         Policy; Background

 

Objectives

 

Through
this document, the Company will determine and publish its policy with regards to the compensation of its Office Holders, including
all components of compensation, while establishing principles, considerations, parameters and rules for the determination of Office
Holders’ terms of tenure by the Company’s organs during the application period of this compensation policy. The policy
is presented to the Company’s general meeting of the shareholders (the “General Meeting”) and subject
to their approval, thereby providing an opportunity for shareholders to influence the method used to determine the compensation
of Office Holders, and to express their opinion on the matter. The publication of the compensation policy increases and improves
the effectiveness of the Company’s disclosure to its investors and to the capital market. In addition to the foregoing,
the compensation policy is intended to comply with the obligation set forth in the Israeli Companies Law, 5759-1999 (hereinafter:
the “Companies Law”).

 

Application
of the Compensation Policy

 

In
accordance with the provisions of the Companies Law, the compensation policy will apply with respect to the terms and conditions
of the tenure and employment of the Office Holders in the Company. The definition of Office Holders in the Companies Law
includes “a general manager, chief business manager, deputy general manager, vice general manager, any person filling
any of these positions in a company even if he holds a different title, as well as a director, or a manager directly subordinate
to the general manager.” For the purpose of this policy, each Office Holder other than a director shall be referred
to as an “Executive”.

 

The
compensation policy is not intended to establish personal terms and conditions for specific Office Holders, but rather to set
forth objective principles and parameters which will apply to all Company’s Office Holders. This policy sets forth maximum
amounts only, and nothing in this policy shall obligate the Company to grant any particular type or amount of compensation to
any Office Holder, unless expressly stated otherwise, nor shall it derogate from approval procedures mandated by law.

 

In
accordance with the provisions of the Companies Law, the compensation policy is subject to approval every three years. Therefore,
the current compensation policy shall be valid for a period of three years from the date of its approval by the General Meeting
or as otherwise required by the Companies Law. The Company may, pursuant to the Companies Law, amend or renew the compensation
policy within that period of implementation, subject to an approval at the General Meeting or as otherwise required by the Companies
Law.

 

It
should be noted that, by law, contractual agreements with Office Holders regarding the terms and conditions of their tenure and
employment which were approved prior to the approval of this compensation policy shall continue to apply, and do not require additional
approval in accordance with the provisions of this policy.

 

    1

     

    

 

Establishment
and Approval of the Compensation Policy

 

In
accordance with the Companies Law, the responsibility for approving the compensation policy applies with the board of directors,
after the foregoing has considered the recommendation issued by the Company’s compensation committee. The compensation policy
is subject to the approval of the General Meeting (including by a majority of those participants who are not controlling shareholders
or interested parties, as provided in the Companies Law). In accordance with the provisions of the Companies Law, in the event
that the General Meeting does not approve the policy, the board of directors will be entitled to approve the policy based on grounds
provided by the board of directors and the compensation committee, according to which the foregoing action is taken in the Company’s
best interest.

 

Maintenance
of the Compensation Policy 

 

The
holder of the most senior position in the Company in the field of human resources (as of the adoption of this policy - the Chief
Financial Officer) under the supervision of the Company’s compensation committee, is responsible for monitoring any changes
in the Company, in its business environment, in the capital market, in the labor markets, and in other relevant factors, which
may impact the Company’s considerations regarding the determination of compensation for Office Holders. When applicable,
the compensation committee shall convene to discuss the foregoing, and where necessary, present its recommendations for necessary
updates to the policy to the Company’s board of directors.

 

		3.	Characteristics
                                         of the Company and of Its Office Holders

 

Business
Environment and Its Effect on Office Holders’ Compensation

 

As
a public company engaged in the research, development and marketing of medical devices, the Company has two objectives: providing
its clients efficient and safe systems, and maximizing its revenues for the benefit of its shareholders. Further information regarding
the Company’s business activity may be found in the Company’s filings with the Securities and Exchange Commission
(“SEC”).

 

For
fulfilling the Company’s objectives, the Company has established, and may be required to establish further operation centers
outside of Israel and has appointed, and may be required to appoint Office Holders to serve in such centers. In light of the disparities
between acceptable compensation levels and competitive market in Israel and other countries, the quantitative parameters for the
determination of executive compensation are separately addressed regarding Israel and other countries.

 

In
light of this, the Company’s commercial success depends, to a large extent, both on its ability to recruit skilled Office
Holders and employees with unique background and experience in the field of medical devices, and on its ability to provide its
Office Holders and employees with incentives designated for the investment of outstanding personal efforts on their behalf and
for achievement of goals established by the Company’s board of directors. The need to achieve defined regulation and commercialization
milestones emphasizes the necessity in conditioning parts of certain Office Holders’ compensation upon personal achievements.

 

Description
of Office Holders’ Positions

 

A
description of the positions and responsibilities of the Company’s Office Holders to whom this policy may apply may be found
in the Company’s annual reports filed with the SEC.

 

		4.	Compensation
                                         Components and the Balance between them

 

General

 

An
adequate balance between the components of compensation exists when a linkage is maintained between compensation and the creation
of value for the Company’s shareholders, while maintaining the Company’s ability to recruit and maintain talented
Office Holders and incentivizing them to pursue the Company’s objectives. In particular, an appropriate balance between
the fixed component and the variable components avoids excessively emphasizing one component, since excessively emphasizing the
fixed component may result lack of initiative, whereas excessively emphasizing the variable component may encourage the taking
of uncontrolled, unreasonable risks by Office Holders in a manner which is not for the Company’s benefit or which does not
conform with the Company’s objectives.

 

Compensation
Components

 

Fixed
Compensation

 

Fix
compensation is based on a base salary and benefits. The base salary is a fixed amount paid to an Executive on a monthly basis,
regardless of the Executive’s performance. This component constitutes the basis for payment of the additional benefits (as
further elaborated below). Payment of the base salary enables the implementation of flexible and effective incentive plans, while
minimizing risk-taking caused by over-compensation on variable components’ basis. Both the base salary and the additional
benefits must also take into account the prevailing conditions in the Company’s market (“benchmarking”); however,
the Company does not believe this consideration to be dominant, inter alia in the interest of avoiding a “salary
race” between companies in its market. It should be noted that additional benefits are unique and depend upon the prevailing
customs in different countries, and that when the Company engages employment agreements with Executives for positions outside
of Israel, such Executives may be entitled to receive additional benefits according to the prevailing customs in the countries
in which they serve, in order to ensure the competitiveness of the employment terms and conditions offered by the Company relative
to its competitors in the relevant country.

 

    2

     

    

 

Variable
Compensation

 

Cash
variable compensation is one of the components used for achieving the objectives of this compensation policy herein, and particularly
for creating a correlation between the interests of the Company’s Executives and those of the Company and its shareholders.
In order to promote the objectives of this policy herein, the conditions for the payment of bonuses shall reflect the Company’s
short-term and long-term objectives, insofar as possible, and shall constitute a proportionate part of the total compensation
in a manner that constitutes a dominant component in the entire compensation package, and primarily with respect to the fixed
salary component, while not constitute an excessively large portion of such compensation package, in order not to create incentives
for taking uncontrolled or unreasonable personal and organizational risks. In order to create incentives for Executives to achieve
their goals, the variable compensation shall be determined in a manner that links the payment of compensation to short-term and
long-term performance objectives. Although it is common practice to pay bonuses upon achievement of financial goals, the Company’s
objectives for the payment of bonuses may be dependent upon other measurable achievements, such as achieving regulatory milestones,
receiving various authorizations, executing agreements, etc. as well as non-measurable “qualitative” achievements.
Dependency of bonuses upon achievement of non-financial achievement is relevant to a large extent given the Company’s transitional
stage between being a research and development company and a commercial one.

 

Equity-Based
Compensation

 

Equity-based
compensation is used to link between the Company’s value for its shareholders (which is reflected by the increase of the
Company’s price per share) and the compensation of its Office Holders. This component is implemented by one of, or a mix
of, equity compensation such as options, restricted stock units (RSUs), restricted shares and other equity-based compensation.
Equity-based compensation constitutes an incentive over time, as well as an incentive to be employed by the Company over long
periods of time, by setting vesting dates for the granted equity awards, by their expiration pursuant to the termination of the
relevant office holder’s tenure, or by conditioning the grant or vesting of equity awards (or portions thereof) on the achievement
of objectives. Furthermore, accelerated vesting mechanisms may create incentives for Office Holders to remain employed by the
Company and to achieve its objectives even if an extraordinary event, such as the merger or sale of the Company, change of control,
or termination of employment in certain circumstances, is expected. Equity-based compensation is an important component in this
compensation policy herein, since it is common practice in comparative companies and is important to the Company’s ability
to recruit and retain Office Holders, it is an efficient substitute for cash compensation, and is especially appropriate since
some of the operations which are crucial for the Company’s success are long-term ones, and some of the Company’s Office
Holders’ efforts may only bear fruit over long periods of time.

 

Termination-Based
Compensation

 

Compensation
paid upon the termination of tenure is used both as an incentive to recruit talented Executives by reducing their exposure upon
terminations of their service due to various circumstances, as well as an incentive for Executives to serve in the Company for
long periods of time, should the compensation be dependent upon seniority.

 

		5.	Considerations
                                         and Parameters for the Determination of Compensation

 

General
Considerations for the Determination of Executive’s Compensation

 

When
determining the compensation of an Executive, the Company’s board of directors, compensation committee and management shall
comply with the guidelines stipulated by this policy herein, including regarding the cap on the compensation components and the
quantitative parameters which have been determined in this section below, and will also consider the following factors (in addition
to any other relevant factor):

 

(i) The
Executive’s personal data, including his education, skills, expertise, and professional experience and achievements,
whether in the Company or in other companies, as well as his uniqueness in the market; for this purpose, it should be noted that
the medical devices market requires employment of Executives who hold unique experience and expertise, including experience working
with regulatory entities such as the FDA, experience in conducting clinical experiments, experience in marketing medical devices
to customers such as hospitals, and managing engagements for the purpose of medical reimbursement outside of Israel;

 

(ii) The
Executive’s position, characteristics, responsibilities, efforts required for success in the position, the extent to
which such Executive is essential for the Company’s success, the possibility to recruit a replacer for his position, the
potential damage to the Company in the event the Executive is dismissed or resigns, his seniority and previous compensation arrangements
with the Company;

 

(iii) The
Executive’s residential address and address of service – if the Executive resides in a country in which the prevailing
compensation in the relevant market for his position is higher than its equivalent in Israel or in which the living conditions
are more difficult or easy than the ones in Israel, the compensation, including any benefits, shall be adjusted to take into account
all such differences;

 

    3

     

    

 

(iv) Prevailing
salary levels for similar positions in the market – in order to ensure the Company is competitive and recruits appropriate
and high-quality personnel, it must offer a salary at a level which corresponds with the prevailing salary in its market. The
foregoing is particularly relevant to the medical devices market, which requires unique experience and skills, available by a
limited number of office holders. The Company’s market includes medical device companies, and particularly such companies
which received material regulatory approvals and are focusing their efforts in commercializing their respective products worldwide;
public companies whose market value, the nature of their operations or their revenue, is similar to those of the Company; and
companies which primarily operate in the United States and in Europe, and which employ Executives serving and operating in these
areas; and

 

(v) The
ratio between Executive’s compensation cost and the Salary Cost of other Company’s employees (including the Company’s
Contract Employees1), and particularly the ratio between the compensation cost of the foregoing Executives
and the average and the median Salary Costs of employees and the effect such ratios have on the working relations in the Company;
the Company acknowledges it has to pay different levels of compensation to its various employees and Executives, inter alia
for the purpose of recruiting talented and experienced Executives and employees who constitute key personnel for the achievement
of the Company’s objectives. It should be noted that where Executives reside and serve in such countries in which higher
compensation than the one available in Israel is paid in accordance with customary market terms, the Company shall consider such
higher compensation levels in its evaluation of the above ratios.

 

Establishment
of Fix Compensation

 

The
base salary shall be negotiated by the Company and the relevant Executive prior to his or her appointment for office, and upon
the Company’s periodic evaluation of his or her base salary during his or her tenure. The base salary shall be based upon
the parameters specified above, provided that the base salary shall not deviate from the pre-determined cap for such Executive,
as further elaborated below.

 

In
addition to the base salary, the Company may include the following benefits, provided that such benefits, including the following
will be in accordance with applicable law and common practice in the market from time to time: (i) vacations days (or redemptions
thereof); (ii) allocations to pension and/or insurance funds, including loss of working capacity insurance; (iii) education funds
(Keren Hishtalmut); (iv) directors’ and officers’ insurance; (v) reimbursement for employment of service related expenses;
(vi) company vehicle (type of vehicle will be determined according to the Executive’s position), including reimbursement
of all related expenses, and tax payments incurred in connection with the vehicle as shall be in effect from time to time (or,
alternatively, reimbursement of expenses in private vehicle, which shall not exceed the cost of company vehicle and all related
costs; (vii) internet, laptop computer, cellular telephone for personal use, home phone expenses and daily newspaper; (viii) accommodation
during employment or service related travels; (ix) mandatory allocations such as recuperation pay (Dmei Havra’a);
and (x) office holders’ indemnification and exemption of liability in accordance with the Companies Law, the Company’s
Articles of Association and the Company’s policy from time to time.

 

Executives
who serve outside of Israel (including such Executives who serve in the Company’s U.S. subsidiary or in such other subsidiaries
which may exist from time to time) may be entitled to benefits in accordance with applicable custom and practice in their country
of service and for Executives of similar rank; Accordingly, Executives serving in the United States will be entitled to medical
and dental insurance coverage for the Executive and his immediate family, which shall be paid by the Company, as well as employer’s
allocations for 401(k) funds, as well as similar or parallel benefits as customary in other global locations.

 

Establishment
of Performance-Related Cash Variable Compensation

 

The
Company shall establish parameters and conditions for the payment of an annual cash bonus, including maximum bonus amounts and
the maximum percentage of the annual fixed compensation such bonuses may include, on an annual, or multi annual, basis and threshold
conditions for payment.

 

Eligibility
for the annual cash bonus shall be based upon measurable criteria, which may include financial results (such as revenue, profit
or fund raising targets) and milestones such as regulatory approvals, agreement executions (such as licenses or distribution or
collaboration agreements), performance of medical procedures and other business millstones (such as number of procedures or MD
training). Additionally, the Company may determine that, with respect to the chief executive officer (the “CEO”)
or an officer who is a director, that a non-material portion of his or her annual cash bonus will be based on the evaluation of
the board of directors in an amount that will not exceed, with respect to any calendar year, 25% of the annual fixed compensation,
and, with respect to any officer subordinated to the CEO, which does not serve as a director, a portion or all of his or her annual
cash bonus will be based on the evaluation of the CEO.

 

 

	1	“Contract Employees” shall mean employees of a Manpower Contractor of whom the
Company is, in practice, the employer, and employees of a Service Contractor who are hired by the Company for the provision of
services; for this purpose, the meaning of “Manpower Contractor” and “Service Contractor”
are as defined in the Engagement of Employees by Manpower Contractors Law, 5756-1996. For the purposes of this Section herein,
“Salary Cost” shall mean any payment paid for employment including employer contributions, retirement payments,
vehicle and related expenses, and any other benefit or payment.

 

    4

     

    

 

In
the event of a new hired Executive or of an Executive who’s engagement ends during the year, his entitlement to an annual
cash bonus may be determined on a pro rata basis. The Company may also determine threshold conditions which, unless met, will
not result in payment of any bonuses.

 

At
the end of each year, the Company shall evaluate the rate of objectives met during the preceding year. In the event that an Executive
met all of his pre-determined objectives, such Executive shall be entitled to receive 100% of his performance-related compensation
component, and in the case of a partial achievement of such objectives, or of some of the objectives, the Company shall pay a
proportional part of such maximum component, provided that the applicable threshold conditions for payment were also met.

 

In
addition to the annual cash bonus specified above, the compensation committee and the board of directors may, from time to time
and to the extent they deem it is required, approve payment of a signing bonus or a special bonus for an office holder either
under special circumstances, for special contributions, achievements or assignments or in the event of a change in control of
the Company. The Company considers payment of such signing and special bonuses as an important tool for providing incentives for
its Executives, especially in light of the inability to foresee all the specific grounds for payment of bonuses pursuant to the
principles set forth in this compensation policy herein.

 

The
payment of variable compensation shall be subject to the provision of a written undertaking by the Executive receiving such variable
compensation to repay any amount of such variable compensation paid to him based on data which has later been found to be incorrect,
and which has been restated in the Company’s financial statements within a period of three years following the grant of
such performance related compensation. The compensation committee and the board of directors shall be authorized not seek recovery
to the extent that (i) to do so would be unreasonable or impracticable or (ii) there is low likelihood of success under governing
law versus the cost and effort involved; the aforementioned undertaking shall be in accordance with any general claw-back policy
as may be adopted by the Company.

 

Establishment
of Equity-Based Compensation

 

Equity-based
compensation is an effective tool, designated for the creation of incentives for Office Holders, which correspond with the long-term
objectives of the Company and its shareholders. Stock options are currently appropriate key equity based compensation vehicle.
In the future, the Company may offer various types of equity based compensation vehicles (e.g. restricted shares, restricted share
units, phantom shares, performance shares, performance share units, etc.) as well as a mix between such vehicles. When determining
the types of equity- based vehicles and the mix between them, if any, the Company will consider among other things, the types
of equity awards then available to the Company and the balance between aligning officer’s and shareholder’s interests
and the Company’s risk management policy at the time.

 

To
the extent legally available and applicable, the Company will grant options to its Israeli residents Officer Holders in accordance
with Section 102 of the Israeli Income Tax Ordinance [New Version], 5721-1961 and/or means of other equity-based compensation,
which may promote the Company’s objectives, as determined by the board of directors. Office holder receiving such equity-based
compensation shall bear any applicable tax. Reference to “options” in this compensation policy shall also include
other means of equity-based compensation which may be provided in the future.

 

Grant
of options shall be in accordance with and subject to the terms of the Company’s current or future applicable equity-based
compensation plans, and when granting options to office holders, the Company shall set the following conditions:

 

(i) Maximum
Grant Date Value of Options Granted to Each Office Holder – such value will be subject to the cap on equity grants,
as further elaborated below.

 

(ii) Maximum
Dilution Rate of the Company’s Share Capital – the maximum dilution rate may not exceed 10% of the Company’s
share capital on a fully diluted basis.

 

(iii) Vesting
/ Minimum Holding Period – options granted will vest over periods ranging from once a month to once a year, and will
become fully vested over several years (e.g., two (2) to four (4) years) but no less than two (2) years from the date of grant.
The company may set accelerated vesting terms and conditional vesting terms for the options granted.

 

(iv) Conditional
Vesting / Objective Dependent Exercise – the Company will consider adoption of conditional vesting and/or objective
dependent exercise of options, in consideration of the Office Holder’s position. Notwithstanding the aforementioned, the
Company is not obligated under this compensation policy to condition the grant or exercise of options granted upon the achievement
of personal or Company objectives. Such objectives may be identical to, or different from, the objectives set by the Company for
the payment of annual or special cash bonuses and may be adjusted, when applicable, following major acquisitions, divesture, organizational
changes or material changes in the Company’s business environment. To the extent that options’ vesting is conditioned
upon the achievement of objectives, the Company may determine that such options will become fully vested upon the achievement
of the relevant objective, rather than by the lapse of vesting periods.

 

    5

     

    

 

(v) Exercise
Price for stock options – will be set as an incentive to maximize the Company’s value, and will be equal to, or
higher than, the price per share in the stock exchange determined by the board of directors on the date of grant, or will be equal
to the average price per share during a pre-determined period prior to the grant approval date as determined by the board of directors.

 

The
board of directors shall have the discretion to reduce, cancel or suspend payment of any variable compensation components, in
cases where such reduction, cancellation or suspension of payment is deemed necessary. In addition, the board of directors may
set a maximal exercise value of variable components which are not exercised in cash.

 

Establishment
of Relocation Compensation

 

Relocation
compensation may be granted to an Executive under relocation circumstances. Such compensation may include reimbursement for out
of pocket one time payments and other ongoing expenses, such as travel, housing allowance, car or transportation allowance, home
leave visit, healthcare, participation in children tuition fees etc., all as reasonable and customary for the relocated country.

 

		6.	Compensation
                                         Components Caps

 

General

 

The
fixed and variable compensation components will be subject to the following:

 

(i) The
fixed compensation maximum rates stated in this policy refer to provision of services on a 100% basis and consist of base salary
and any benefits available under this compensation policy.

 

(ii) The
annual bonus cap stated in this policy refers to the target annual bonus to be granted upon achievement of 100% of the objectives
for payment of such annual bonus.

 

(iii) In
the case of equity-based compensation, the cap stated in this policy refers to the value of the options granted (or of other means
of such compensation) as of the date of grant based on acceptable valuation practices at
the time of grant utilizing the straight line approach per year of vesting (taking into account the cost of previous vesting
grant for that year).

 

Non-Executive
Directors

 

The
Company’s non-executive directors may be compensated by means of (i) an annual payment of up to NIS 111,345, and by means
of payment for participation in Board (or committees) meetings up to an amount of NIS 4,285 per meeting, or (ii) an annual payment
of up to NIS 175,620, which will include payment for participation in Board (or committees) meetings. Such directors may also
be entitled to receive equity-based compensation in accordance with any applicable law, but will not be entitled to receive performance-based
compensation, such as bonuses. The Company may repay director’s expenses in accordance with any applicable law.

 

The
caps on each of the non-executive directors’ compensation components per year are as follows:

 

	Variable
    Equity-based Compensation	 	Annual
    Bonus	 	Signing
    and Special Bonus
	up
    to 100% of the annual payment described in clause (ii) above 	 	Not
    Applicable	 	Not
    Applicable

 

Chief
Executive Officer

 

The
CEO’s fixed compensation shall range between the following amounts: (i) a CEO whose position is primarily in Israel: up
to NIS 170,000, per month, and (ii) a CEO whose position is primarily in the United States or Europe2: up to NIS
250,000, per month.

 

The
caps on the CEO’s variable compensation components per year are as follows:

 

	Variable
    Equity-based Compensation	 	Annual
    Bonus	 	Signing
    and Special Bonus
	Up
    to 100% of the annual fixed compensation	 	Up
    to 50% of the annual fixed compensation	 	Up
    to 50% of the annual fixed compensation

 

Special
and signing bonuses will not be included in the calculation of the maximum annual bonus.

 

 

	2	For the purposes of this compensation policy herein, the NIS-USD and NIS-EUR exchange rates
shall be as follows: USD 1 = NIS 3.7; EUR 1= NIS 4.2.

 

    6

     

    

 

Other
Executives

 

Other
Executive’s fixed compensation shall range between the following amounts: (i) an Executive whose position is primarily in
Israel: up to NIS 120,000, per month, and (ii) an Executive whose position is primarily in the United States or Europe: up to
NIS 170,000, per month.

 

The
caps on other Executive’s variable compensation components per year are as follows:

 

	Variable
    Equity-based Compensation	 	Annual
    Bonus	 	Signing
    and Special Bonus
	Up
    to 100% of the annual fixed compensation 	 	Up
    to 50% of the annual fixed compensation	 	Up
    to 50% of the annual fixed compensation

 

Special
and signing bonuses will not be included in the calculation of the maximum annual bonus.

 

Termination
of Services

 

Executives
shall be entitled to an advance notice period in accordance with existing agreements, and, in the absence of provisions in the
agreements, as determined by the law. In any event, the advance notice period shall not exceed six (6) months. During said notice
period, Executives will be required to continue to fulfill their duties, unless the Company decides to release them from this
obligation.

 

In
addition to any payments required under any applicable law upon termination of service, vesting of outstanding options and payment
of an additional severance bonus may be included in office holder’s employment agreement, or may be paid upon Executive’s
severance, subject to receipt of all required approvals. The Company will consider payment of a severance bonus in consideration
of the objectives of this compensation policy herein, as well as: (i) the service period of the Executive in question; (ii) the
Executive’s terms and conditions of service; (iii) the Company’s operations during Executive’s service; (iv)
the Executive’s contribution to the achievement of the Company’s objectives and to its profitability; and (v) the
circumstances of the severance.

 

The
maximum severance bonus that may be paid by the Company is as follows: (i) non-executive directors will not be eligible for severance
bonus, (ii) the CEO may be entitled to a severance bonus of up to 50% of the annual fixed compensation, and (iii) other Executives
may be entitled to a severance bonus of up to 25% of the annual fixed compensation. An Executive’s severance bonus will
be based on his last monthly salary as of the termination date of his service and his or her termination of service must not be
in circumstances which, in the Company’s opinion, justify severance pay to be revoked.

 

		7.	Directors’
                                         and Officers’ Liability Insurance, Indemnification and Exemption

 

The
Company may provide its directors and officers, including those serving in any of its subsidiaries from time or time, with a liability
insurance policy (the “Insurance Policy”) provided that the engagement is in the ordinary course of business,
in market terms and is not expected to materially influence the Company’s profits, properties and undertakings. The coverage
limit of the Insurance Policy shall be of up to US$30 million per occurrence and for the insurance period (additional coverage for
legal expenses not included), provided that the annual premium shall not exceed US$500,000 and that the deductible (except for extraordinary
matters as prescribed in the Insurance Policy, such as lawsuits against the Company pursuant to securities laws and/or lawsuits
to be filed in the US/Canada) shall not exceed US$1,000,000 per occurrence.

 

The
Company may extend the Insurance Policy in place to include cover for liability pursuant to a future public offering of securities.
The additional premium for such extension of liability coverage shall not exceed 400% of the last paid annual premium. The Insurance
Policy, as well as the additional premium shall be approved by the compensation committee (and if required by law, by the board
of directors) which shall determine that the sums are reasonable considering the exposures pursuant to such public offering of
securities, the scope of cover and the market conditions and that the Insurance Policy reflects the current market conditions,
and it does not materially affect the Company’s profitability, assets or liabilities.

 

Upon
circumstances to be approved by the compensation committee (and, if required by law, by the board of directors), the Company shall
be entitled to enter into a “run off” Insurance Policy of up to seven (7) years, with the same insurer or any other
insurance (the “Run Off Coverage”). The limit of liability of the insurer shall not exceed US$30 million per
claim and in the aggregate for the term of the policy, the premium for the insurance period shall not exceed 400% of
the last paid annual premium and the deductible (except for extraordinary matters as prescribed in the Insurance Policy, such
as lawsuits against the Company pursuant to securities laws and/or lawsuits to be filed in the US/Canada) shall not exceed US$1,000,000
per claim. The Run Off Coverage, as well as the limit of liability and the premium for each extension or renewal, shall be approved
by the compensation committee which shall determine whether the sums are reasonable considering the Company’s exposures,
the scope of coverage and market conditions and if the Run Off Coverage reflects then prevailing market conditions, and, provided,
further, that the Run Off Coverage shall not materially affect the Company’s profitability, assets or liabilities.

 

    7

     

    

 

In
addition, the Company may exempt all directors and officers, as may be appointed from time to time in the future, from liability
for a breach of their duty of care to the Company and provide them with indemnification to the fullest extent permitted by law
and the Company’s articles of association.

 

		8.	Miscellaneous

 

The
Company’s compensation committee and board of directors shall be authorized to approve a deviation of up to 10% from any
limits, caps or standards detailed in this policy, and such deviation shall be deemed to be in alignment with this policy.

 

An
Immaterial Change in the Terms of Employment of an Executive, which is not a director or the CEO may be approved by the CEO, provided
that the amended terms of employment are in accordance with this policy. An “Immaterial Change in the Terms of Employment”
means a change in the terms of employment of an officer with an annual total cost to the Company not exceeding an amount equal
to 20% of the annual fixed compensation of such Executive.

  

ADOPTED:
__________________

 

    8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]